EP0217207B1 - In 6- und 9-Stellung substituierte 2-Aminopurine, ihre Verwendung, diese Purine enthaltende Arzneimittel und Verfahren zur Herstellung der Purine - Google Patents

In 6- und 9-Stellung substituierte 2-Aminopurine, ihre Verwendung, diese Purine enthaltende Arzneimittel und Verfahren zur Herstellung der Purine Download PDF

Info

Publication number
EP0217207B1
EP0217207B1 EP86112688A EP86112688A EP0217207B1 EP 0217207 B1 EP0217207 B1 EP 0217207B1 EP 86112688 A EP86112688 A EP 86112688A EP 86112688 A EP86112688 A EP 86112688A EP 0217207 B1 EP0217207 B1 EP 0217207B1
Authority
EP
European Patent Office
Prior art keywords
compounds
carbon atoms
compound
amino
halogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP86112688A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0217207A1 (de
Inventor
Erhardt Dr. Winkelmann
Heinrich Dr. Rolly
Irvin Dr. Winkler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Priority to AT86112688T priority Critical patent/ATE62486T1/de
Publication of EP0217207A1 publication Critical patent/EP0217207A1/de
Application granted granted Critical
Publication of EP0217207B1 publication Critical patent/EP0217207B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems

Definitions

  • Medicaments which contain 2-amino-6-hydroxy-9- (2-hydroxyethoxymethyl) purine (acyclovir - see FIG. 1, formula ACV in the tautomeric oxo notation) as active ingredient. These are good anti-herpes agents (cf. EP-OS 72 027).
  • Drugs for viral infections were later developed which differ from those of the formula ACV in that, in addition to the ether group in the hydroxyethyl radical, they additionally contain a hydroxymethyl group, which is a glycerol derivative, with the oxygen in the 6-position also additionally Sulfur can be replaced. (see J. Med. Chem. 28, 358 (1985)). Finally, such compounds have been further modified in such a way that the hydroxymethyl group has been etherified by a benzyl group and the oxygen in the 6-position has optionally been replaced by an imino group (cf. EP-OS 152 965).
  • R ' is hydrogen, halogen, hydroxyl, mercapto, azido, amino or ZR 5 , where Z is oxygen, sulfur, Sulfinyl, sulfonyl or NH and R 5 is an acyclic aliphatic hydrocarbon radical having 1 to 6 carbon atoms, which a) is unsubstituted or b) is modified by at least one of the features that it has an alkoxy group with 1 to 3 carbon atoms or a double bond contains or is at least partially fluorinated, or represents cycloalkyl with 3 to 6 carbon atoms or phenylalkyl with an alkylene group of 1 to 3 carbon atoms or phenyl, where the phenyl ring in each case at most twice, preferably at most once, by a substituent from the group halogen, Trifluoromethyl, alk oxy and alkylthi
  • the acyclic hydrocarbon radical preferably contains 3 to 5 carbon atoms and the cycloaliphatic radical mostly contains 4 to 6 and in particular 5 to 6 carbon atoms.
  • the radicals R 4 to R 6 , substituents contained in the phenyl radicals, the radicals R 'and R 3 and X and Y can each be the same or different.
  • Aliphatic hydrocarbon radicals, alkoxy radicals and alkylene groups in the phenylalkyl radicals can each be straight-chain or branched, but these are preferably straight-chain in the phenylalkyl radicals.
  • Halogen in the radicals R 'and R 3 is fluorine, chlorine, bromine or iodine.
  • Halogen is preferably chlorine or bromine in the radical R 1 and fluorine or chlorine in the radical R 3 .
  • the at least partially fluorinated alkyl radicals have, for example, 1 to 4, preferably two, carbon atoms, the partially fluorinated radicals being particularly preferred, for example -CH 2 -CF 3 .
  • EP-OS 145 207 The compounds in which R 'OH or SH, R 2 H, R 3 YR 4 , X 0 or S, Y 0 and R 4 are alkyl having 1 to 8 carbon atoms are known from EP-OS 145 207 and also their use as medicines for the treatment of autoimmune diseases such as arthritis, multiple sclerosis, etc., as well as viral infections and cancer.
  • the cited EP-OS 145 207 also describes, and mainly claims, those which contain a bromine atom or an NH 2 or NHCOR 6 group in the 8-position, where R 6 is a C 1 -C 4.
  • -Alkyl radical, an aryl radical or an aralkyl radical are examples of alkyl having 1 to 8 carbon atoms.
  • reaction step 22 (2) to 23 (2) the benzyl radical is removed as a protective group by catalytic hydrogenation.
  • an alkyl group such as isopropyl group
  • the benzyl group can be split off as toluene, but not aliphatic ether groups.
  • the compounds according to the invention Compared with the compounds known from EP-OS 145 207, substituted in the 8-position and unsubstituted in the 8-position and also with respect to the compound of the formula Z, the compounds according to the invention have the advantage of being considerably more effective. This means that, with the same or improved toxicity, significantly smaller amounts of the active ingredients can be used.
  • the compounds of general formula 1 according to the invention can be prepared by various methods, depending on the meaning of the radical R 1, different starting materials and suitable protective groups being selected.
  • Some embodiments (A to D) and the formula names given below are shown in the reaction scheme (FIG. 2), in which HMDS denotes hexamethyldisilazane, pyr pyridine and Ac acetyl and in the formulas in which R 1 denotes OH, SH or NH 2 , a spelling in tautomeric form according to formulas 2 ', 3' and 6 '(see FIG. 1) would also be possible.
  • the halogen is preferably chlorine, although it can also be another, such as bromine.
  • the starting materials of the formulas 13 and 14 are predominantly known and can be prepared by known methods (see Examples 1 a-d and 3a-g).
  • the halogen in the a-position to X in particular chlorine, is notable a special reactivity.
  • other trialkylsilyl protecting groups can also be used instead of the trimethylsilyl protecting group, in which the alkyl radical has, for example, 1 to 6, preferably 1 to 3, carbon atoms and is straight-chain or branched.
  • the compounds 15, 19 and 20 according to the invention are optionally saponified to give other compounds of the formula 1 in which R 2 is hydrogen instead of acyl (see FIG. 2).
  • R 1 is hydroxy (or oxo) (formula 9), mercapto (or thio) (formula 10), amino (or imino) (formula 6a) or hydrogen (formula 7a) - see. 1 is in each case, corresponding di- or triacyl compounds of the formulas 9, 10, 6a or 7a are reacted with reactive acetoxy compounds of the formula 14, in which R 2 is acyl and X and R 3 have the meaning given. Compounds of the formulas 16, 17, 6b and 7b substituted in the 9-position are thus obtained. These compounds of the invention are optionally saponified to give other compounds of the formula 1 in which R 2 is hydrogen.
  • R 1 is H, OH or NH 2
  • R 2 are acyl, in particular acetyl, and XO or S are preferred for process C, where R 3 and thus also Y and R 4 have the meaning given in claim 1 .
  • reaction temperatures are generally between 0 and 150 ° C., preferably between 50 and 100 ° C. Usually one works at normal pressure, but it is also possible to work at elevated or reduced pressure, although there are normally no advantages.
  • the solvents and distributing agents can of course be used both in the form of uniform substances and in the form of mixtures. The following is carried out for the individual processes:
  • the reactions according to process A) are expediently carried out in a solvent or distribution medium.
  • Aprotic solvents such as benzene, toluene
  • a base such as triethylamine or N-ethylmorpholine is recommended to trap the hydrohalic acid formed.
  • the reaction times range from a few minutes to several hours, usually 12-24 hours.
  • the use of a protective gas in the reaction vessel e.g. Nitrogen or argon.
  • the trialkylsilyl protecting groups can be split off e.g. by boiling the intermediate compound with an alcohol such as methanol or ethanol.
  • the reactions according to process B) are also advantageously carried out in a solvent or distribution medium.
  • sulfones are particularly suitable as aprotic solvents, such as sulfolane (tetramethylene sulfone) or dipropyl sulfone.
  • an acidic catalyst such as methane, ethane, benzene or toluene sulfonic acid is recommended.
  • the reaction times are usually several hours to a few days.
  • the reactions according to process C are also advantageously carried out in a solvent or distribution medium.
  • Polar, aprotic solvents such as dimethylformamide, dimethylacetamide, tetramethylurea, hexamethylphosphoric triamide or dimethyl sulfoxide are particularly suitable for this.
  • a base e.g. those mentioned below in the hydrolysis, such as triethylamine, N-ethylmorpholine or alkali metal carbonates, such as sodium or potassium carbonate.
  • the reaction times are several minutes to several hours.
  • Method D To the extent according to one of the methods A to C.
  • Compounds according to the invention such as 15 to 20, 6b and 7b can be obtained, for example by the action of bases such as ammonia, alkylamines such as methyl or ethylamine, the various propyl or butylamines, or alkali metal hydroxides or carbonates such as sodium hydroxide, potassium hydroxide , Sodium carbonate, potassium carbonate in aqueous or alcoholic (methanol, ethanol) solution, generally at temperatures of 0-100 C, preferably at 20-50 C.
  • bases such as ammonia, alkylamines such as methyl or ethylamine, the various propyl or butylamines, or alkali metal hydroxides or carbonates
  • sodium hydroxide potassium hydroxide
  • Sodium carbonate, potassium carbonate in aqueous or alcoholic (methanol, ethanol) solution generally at temperatures of 0-100 C, preferably at 20-50 C.
  • the compounds according to the invention have an optically active (chiral) center on the carbon 2 atom in the ether side chain.
  • the compounds are present as racemates (DL form). It is possible to produce or isolate the optically active antipodes (enantiomers).
  • the compounds of formula 1 according to the invention have valuable pharmaceutical properties. They are effective in vitro and in vivo against various viruses and are therefore suitable for combating various diseases caused by DNA viruses, such as herpes, e.g. B. type simplex 1 and 2, cytomegaly and RNA viruses, e.g. B. retroviruses, as well as autoimmune diseases and for the treatment of cancer.
  • Medicinal products containing them can be used enterally (orally), parenterally (intravenously), rectally or locally (topically). They can be administered in the form of solutions, powders (tablets, capsules including microcapsules), ointments (creams or gel) or suppositories.
  • auxiliaries for such formulations are the pharmaceutically customary liquid or solid fillers and extenders, solvents, emulsifiers, lubricants, taste correctives, colorants and / or buffer substances.
  • 0.1-10, preferably 0.2-8 mg / kg body weight are administered. They are expediently administered in dosage units which contain at least the effective daily amount of the compounds according to the invention, e.g. Contain 30-300, preferably 50-250 mg.
  • the compounds according to the invention can also be administered in combination with other antiviral agents and immunostimulants, such as interferons.
  • NMRI mice specifically pathogen-free, weighing about 15 g, were infected intraperitoneally with herpes simplex type 1 and then treated intraperitoneally with the compounds described.
  • Acyclovir (ACV) was always used as a comparison.
  • Treatment was given twice a day for 5 days, starting after infection. The success of treatment was determined on the basis of the course of the disease and the survival rate compared to the untreated infection controls.
  • the latter received a water-soluble methylhydroxyethyl cellulose (viscosity 300 Pa * s in 2% solution) ( (R) Tylose MH 300 P) instead of the compounds to be tested.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP86112688A 1985-09-24 1986-09-13 In 6- und 9-Stellung substituierte 2-Aminopurine, ihre Verwendung, diese Purine enthaltende Arzneimittel und Verfahren zur Herstellung der Purine Expired - Lifetime EP0217207B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT86112688T ATE62486T1 (de) 1985-09-24 1986-09-13 In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine.

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE3533983 1985-09-24
DE3533983 1985-09-24
DE3614902 1986-05-02
DE3614902 1986-05-02
DE19863627024 DE3627024A1 (de) 1985-09-24 1986-08-09 In 6- und 9-stellung substituierte 2-aminopurine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
DE3627024 1986-08-09

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP90113147.4 Division-Into 1990-07-10

Publications (2)

Publication Number Publication Date
EP0217207A1 EP0217207A1 (de) 1987-04-08
EP0217207B1 true EP0217207B1 (de) 1991-04-10

Family

ID=27193541

Family Applications (2)

Application Number Title Priority Date Filing Date
EP86112688A Expired - Lifetime EP0217207B1 (de) 1985-09-24 1986-09-13 In 6- und 9-Stellung substituierte 2-Aminopurine, ihre Verwendung, diese Purine enthaltende Arzneimittel und Verfahren zur Herstellung der Purine
EP90113147A Withdrawn EP0400686A1 (de) 1985-09-24 1986-09-13 2-Amino-9-[1,3-bis-(isopropoxy)-propyl-2-oxymethyl]-purin, seine Verwendung und diese Verbindung enthaltende Arzneimittel

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP90113147A Withdrawn EP0400686A1 (de) 1985-09-24 1986-09-13 2-Amino-9-[1,3-bis-(isopropoxy)-propyl-2-oxymethyl]-purin, seine Verwendung und diese Verbindung enthaltende Arzneimittel

Country Status (10)

Country Link
EP (2) EP0217207B1 (da)
KR (1) KR870003108A (da)
AU (2) AU602464B2 (da)
DE (2) DE3627024A1 (da)
DK (1) DK453686A (da)
ES (1) ES2001697A6 (da)
GR (1) GR862409B (da)
HU (1) HU198485B (da)
IL (1) IL80109A0 (da)
PT (1) PT83419B (da)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8602346D0 (en) * 1986-01-30 1986-03-05 Wellcome Found Antiviral combinations
DE3722802A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag In 6- und 9-stellung substituierte 2-amino-8-aza-purine, ihre verwendung, diese purine enthaltende arzneimittel und verfahren zur herstellung der purine
AP160A (en) * 1987-08-15 1991-11-18 The Wellcome Foundation Ltd Therapeutic acyclic nucleosides.
US5216141A (en) * 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
DE3906357A1 (de) * 1989-03-01 1990-09-06 Boehringer Mannheim Gmbh Neue acyclische nucleosid-analoga, verfahren zu ihrer herstellung und verwendung dieser verbindungen als antivirale arzneimittel
DE4008858A1 (de) * 1990-03-20 1991-09-26 Hoechst Ag Substituierte purine, verfahren zu ihrer hertellung sowie ihre verwendung als antivirale mittel
US5206351A (en) * 1990-06-15 1993-04-27 Ash Stevens, Inc. Process for the preparation of 2-amino (2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl)adenine
DE4020481A1 (de) * 1990-06-27 1992-01-02 Hoechst Ag Verfahren zur herstellung von substituierten acyclischen nukleosiden und dabei auftretende zwischenprodukte
US5565565A (en) * 1994-08-04 1996-10-15 Syntex (U.S.A.) Inc. Preparation of N-9 substituted guanine compounds
AU709345B2 (en) 1995-09-07 1999-08-26 Emory University Therapeutic azide compounds
US6040446A (en) * 1996-01-26 2000-03-21 Syntex (U.S.A.) Inc. Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
US4287188A (en) 1977-02-24 1981-09-01 Burroughs Wellcome Co. Purine derivatives
US4267188A (en) 1979-08-09 1981-05-12 Merck & Co., Inc. 5-Substituted-1-carba-pen-2-em-3-carboxylic acid
PL247394A1 (en) 1981-08-11 1984-10-22 Wellcome Found Process for preparing derivatives of purine
US5250535A (en) * 1982-02-01 1993-10-05 Syntex Inc. Substituted 9-(1 or 3-monoacyloxy or 1,3-diacyloxy-2-propoxymethyl) purines as antiviral agent
SE8203855D0 (sv) 1982-06-21 1982-06-21 Astra Laekemedel Ab Novel derivatives of guanine i
EP0108285B1 (en) 1982-10-14 1988-04-20 The Wellcome Foundation Limited Antiviral purine derivatives
EP0138683A3 (en) 1983-09-30 1988-01-20 Merck & Co. Inc. Purine derivatives, their application in anti-viral compositions
IE842642L (en) * 1983-10-31 1985-04-30 Harvard College Purine Derivatives
US4621140A (en) * 1984-02-23 1986-11-04 Syntex (U.S.A.) Inc. Process for preparing 2,6-substituted-9-(1,3-dihydroxy-2-propoxymethyl)-purines and certain derivatives

Also Published As

Publication number Publication date
GR862409B (en) 1987-01-20
PT83419A (de) 1986-10-01
EP0217207A1 (de) 1987-04-08
HUT41789A (en) 1987-05-28
AU6305486A (en) 1987-03-26
AU5461890A (en) 1990-11-08
IL80109A0 (en) 1986-12-31
AU602464B2 (en) 1990-10-11
DK453686A (da) 1987-03-25
DE3678657D1 (de) 1991-05-16
KR870003108A (ko) 1987-04-15
PT83419B (pt) 1989-05-12
DE3627024A1 (de) 1987-04-02
ES2001697A6 (es) 1988-06-01
DK453686D0 (da) 1986-09-23
EP0400686A1 (de) 1990-12-05
HU198485B (en) 1989-10-30

Similar Documents

Publication Publication Date Title
DE69033915T2 (de) Xanthinderivate, Verfahren zu ihrer Herstellung und ihre pharmazeutische Anwendung
DE2539963C2 (de) Purinverbindungen, Verfahren zu ihrer Herstellung und pharmazeutische Zubereitungen, welche diese Verbindungen enthalten
DE69012840T2 (de) Adenosin-Derivate, die eine Aktivität gegen Bluthochdruck haben.
DE69132291T2 (de) Xanthinderivate
DD213218A5 (de) Verfahren zur herstellung von 9-(1,3-dihydroxy-2-propoxymethyl)-guaninderivaten
EP0287907A1 (de) Pyrazolo[3,4-d]pyrimidine, Verfahren zu ihrer Herstellung und Verwendung als Arzneimittel
EP0217207B1 (de) In 6- und 9-Stellung substituierte 2-Aminopurine, ihre Verwendung, diese Purine enthaltende Arzneimittel und Verfahren zur Herstellung der Purine
EP0104342A1 (de) Triphenylimidazolyloxyalkansäuren und ihre Derivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Präparate
DE2918261C2 (da)
EP0496238A1 (de) Substituierte Benzoxazepine und Benzthiazepine, Verfahren zu ihrer Herstellung und ihre Verwendung in Arzneimitteln
DE69108408T2 (de) 4,5-dihydroxy und 4,5,8-trihydroxy-9,10-dioxo-2-anthracencarbonsäure-dikohlensäureester und urethane mit therapeutischer wirkung.
EP0341693B1 (de) Verfahren zur Herstellung von O-substituierten Hydroxylaminen
EP0122488B1 (de) Bis-(Piperazinyl- bzw. Homopiperazinyl)-Alkane
EP0491263B1 (de) Phenylalkylaminoalkyl-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0072987A1 (de) Neue cytostatisch wirksame Epoxidgruppen tragende 1,3,2-Oxazaphosphorin-Verbindungen, Verfahren zu ihrer Herstellung sowie ihre Verwendung in pharmazeutischen Zubereitungen
CH632759A5 (de) Verfahren zur herstellung neuer substituierter purine.
EP0452680B1 (de) Substituierte Purine, Verfahren zu ihrer Herstellung sowie ihre Verwendung als antivirale Mittel
EP0044932A1 (de) Gegebenenfalls N-substituierte Amino-desoxy-1.4;3.6-dianhydro-hexit-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung
DE3889248T2 (de) Verfahren zu Herstellung von Purinverbindungen.
DE69308009T2 (de) Derivate des 5,6,7,9-Tetrahydro-1,2,3-trimethoxy-9-oxo-benzo(alpha)heptalens
US4161533A (en) 5-Sulfamoyl-orthanilic acids and process for their preparation
EP0298467A2 (de) In 6- und 9-Stellung substituierte 2-Amino-8-aza-purine, ihre Verwendung, diese Purine enthaltende Arzneimittel und Verfahren zur Herstellung der Purine
EP0260596A2 (de) In 9-Stellung substituierte 2-Amino-6-alkoxy-purine, ihre Verwendung, diese Purine enthaltende Arzneimittel und Verfahren zur Herstellung der Purine
EP0272226A2 (en) 8-Azaxanthines alkylaminoalkyl or heterocyclylalkyl-substituted on the triazole ring, the salts thereof which are physiologically acceptable, their pharmaceutical compositions having antibronchospastic acivity, and the process for preparing the same
DD216013A5 (de) Verfahren zur herstellung neuer ethendiamin- und guanidin-derivate

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

17P Request for examination filed

Effective date: 19870926

17Q First examination report despatched

Effective date: 19890720

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE FR GB IT LI LU NL SE

REF Corresponds to:

Ref document number: 62486

Country of ref document: AT

Date of ref document: 19910415

Kind code of ref document: T

XX Miscellaneous (additional remarks)

Free format text: TEILANMELDUNG 90113147.4 EINGEREICHT AM 13/09/86.

REF Corresponds to:

Ref document number: 3678657

Country of ref document: DE

Date of ref document: 19910516

ITF It: translation for a ep patent filed
ET Fr: translation filed
GBT Gb: translation of ep patent filed (gb section 77(6)(a)/1977)
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19920811

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19920813

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19920817

Year of fee payment: 7

Ref country code: GB

Payment date: 19920817

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19920821

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19920902

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19920903

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19920930

Year of fee payment: 7

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19921114

Year of fee payment: 7

EPTA Lu: last paid annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19930913

Ref country code: GB

Effective date: 19930913

Ref country code: AT

Effective date: 19930913

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19930914

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Effective date: 19930930

Ref country code: CH

Effective date: 19930930

Ref country code: BE

Effective date: 19930930

BERE Be: lapsed

Owner name: HOECHST A.G.

Effective date: 19930930

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19940401

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19930913

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19940531

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19940601

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 86112688.6

Effective date: 19940410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050913